Ligatech Biosciences Closes Hundreds of Millions of Yuan Series D Financing for Sports Medicine

Shanghai-based Ligatech Biosciences closes hundreds of millions of yuan Series D financing led by XindaKunpeng, followed by Sinorock Capital, Jianxin Guomao, and existing shareholder Legend Capital.

Founded in 2014, Ligatech Biosciences focuses on digital sports medicine, completing the entire process layout covering diagnosis, treatment and exercise management. Its main products include cruciate ligament fixation systems, metal wire anchors, PEEK wire anchors, high-strength non-absorbable medical sutures and surgical traction frames.

China’s sports population and the number of people with sports injuries are growing rapidly, as is the number of sports medicine practitioners. China’s annual sports medicine surgeries have exceeded one million units, with an annual growth rate of more than 20%, making it the fastest growing segment within orthopaedics.

After receiving the first domestic approval for artificial ligaments in the first quarter of this year, Ligatech Biosciences has completed the overall layout of all consumables and equipment for sports medicine with its proprietary Digital Biplane X-ray Imaging System. The company’s consumables have been used by more than 2,000 hospitals and small equipment has been installed in 200 hospitals.

The Post is Available in: English – 简体中文

en_GBEnglish (UK)